New Opportunity in a Once Mature Market Now on a Growth Track
Latent TB Diagnostics was the province of a few established companies producing a commodity product. No longer. New technologies. New niche markets.
TB Diagnostics is growing, and in some segments the growth is dramatic. Find out who the new leaders are and what areas are most lucrative. What are the basics of competition?
The report forecasts the market size out five years. Some players have already made their mark but disruptive diagnostic technology could change the playing field. Learn about this market including the issues and outlooks.
This research makes you the expert in your organization. Assistance and additional specific data is provided without additional charge.
Make investment decisions and valuations with confidence using the latest data.
Table of Contents
Companies Mentioned
- AID GmbH
- Beijing Wantai
- bioMérieux Diagnostics
- Boditech Med, Inc.
- Co-Diagnostics
- Danaher
- DiaSorin
- Endo International
- Erythra
- Generium
- Glory Biotechnologies Corp.
- Lionex Diagnostics & Therapeutics GmbH
- LumiraDx
- MDxHealth
- Minute Molecular Dx
- Nanopore
- NGeneBio
- Oxford Immunotec (Perkin Elmer)
- PBD Biotech
- Perkin Elmer
- QIAGEN
- Sanofi
- SD Biosensor
- Serum Institute of India
- Statens Serum Institut
- Zhifei Longcom